Reviewing Mangoceuticals (MGRX) & Its Peers

Mangoceuticals (NASDAQ:MGRX) is one of 18 publicly-traded companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it contrast to its competitors? We will compare Mangoceuticals to related businesses based on the strength of its risk, dividends, earnings, profitability, analyst recommendations, valuation and institutional ownership.

Valuation and Earnings

This table compares Mangoceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Mangoceuticals	$866,792.00	-$9.21 million	-5.93
Mangoceuticals Competitors	$2.39 billion	$82.32 million	13.57

Mangoceuticals’ competitors have higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings for Mangoceuticals and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	0	0	0	0	N/A
Mangoceuticals Competitors	36	288	416	146	2.76

As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 12.49%. Given Mangoceuticals’ competitors higher possible upside, analysts clearly believe Mangoceuticals has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 61.8% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by institutional investors. 39.3% of Mangoceuticals shares are held by insiders. Comparatively, 27.3% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Mangoceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, Mangoceuticals’ competitors have a beta of 3.97, suggesting that their average share price is 297% more volatile than the S&P 500.

Profitability

This table compares Mangoceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-1,053.93%	-243.34%	-200.73%
Mangoceuticals Competitors	-816.62%	-48.14%	-36.60%

Summary

Mangoceuticals competitors beat Mangoceuticals on 9 of the 10 factors compared.

Mangoceuticals Company Profile

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.